Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
ImpactNotable 30/100
Why it mattersRule-based estimate: no strong signals; trust 7/10.
RegionsGlobal
Published3 h ago (Fri, 25 Sep 2026 12:51:39 GMT)
RetrievedFri, 25 Sep 2026 15:00:25 GMT via rss
ClassifiedFri, 25 Sep 2026 15:00:45 GMT by heuristic